Similar articles

• Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.

  Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, Arakawa Y, Hashimoto E, Hirota K, Yoshida H, Ohashi Y, Omata M; Tokyo-Chiba Hepatitis Research Group. Shiratori Y, et al. Ann Intern Med. 2005 Jan 18;142(2):105-14. doi: 10.7326/0003-4819-142-2-200501180-00009. Ann Intern Med. 2005. PMID: 15657158 Clinical Trial.
• Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.

  Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, Berg T, Poo JL, Mello CB, Guenther R, Niederau C, Terg R, Bedossa P, Boparai N, Griffel LH, Burroughs M, Brass CA, Albrecht JK; EPIC3 Study Group. Bruix J, et al. Gastroenterology. 2011 Jun;140(7):1990-9. doi: 10.1053/j.gastro.2011.03.010. Epub 2011 Mar 17. Gastroenterology. 2011. PMID: 21419770 Clinical Trial.
• Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.

  Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S. Papastergiou V, et al. Eur J Gastroenterol Hepatol. 2013 Jul;25(7):798-805. doi: 10.1097/MEG.0b013e32835eb8bf. Eur J Gastroenterol Hepatol. 2013. PMID: 23395996
• [Antiviral treatments during cirrhosis].

  Bronowicki JP. Bronowicki JP. Gastroenterol Clin Biol. 2006 Jun-Jul;30(6-7):899-902. doi: 10.1016/s0399-8320(06)73339-5. Gastroenterol Clin Biol. 2006. PMID: 16885876 Review. French. No abstract available.
• Long-term effects of interferon-based therapy for chronic hepatitis C.

  Yu ML, Huang CF, Dai CY, Huang JF, Chuang WL. Yu ML, et al. Oncology. 2007;72 Suppl 1:16-23. doi: 10.1159/000111703. Epub 2007 Dec 13. Oncology. 2007. PMID: 18087178 Review.